Repotrectinib
Showing 1 - 9 of 9
Trial (Repotrectinib)
Available
- Repotrectinib
- (no location specified)
Jun 30, 2023
Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Canton (repotrectinib (TPX-0005))
Recruiting
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
- repotrectinib (TPX-0005)
-
Canton, OhioGabrail Cancer Research Center
Apr 25, 2023
Advanced Solid Tumor, Metastatic Solid Tumor Trial in Canton (TPX-0005, Metformin Hydrochloride, Digoxin)
Recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- TPX-0005
- +3 more
-
Canton, OhioGabrail Cancer Research Center
Apr 25, 2023
Advanced Cancer, Metastatic Solid Tumor Trial in New York (Repotrectinib, Irinotecan and temozolomide)
Recruiting
- Advanced Cancer
- Metastatic Solid Tumor
- Repotrectinib
- Irinotecan and temozolomide
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Dec 1, 2022
KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor Trial in United States (TPX-0005, Trametinib)
Active, not recruiting
- KRAS Mutation-Related Tumors
- +2 more
-
Los Angeles, California
- +5 more
Nov 7, 2022
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))
Recruiting
- Locally Advanced Solid Tumors
- +3 more
- Oral repotrectinib (TPX-0005)
-
Los Angeles, California
- +27 more
Aug 9, 2022
NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Repotrectinib
- Crizotinib
-
Augusta, Georgia
- +40 more
Nov 29, 2023
Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Worldwide (Oral repotrectinib (TPX-0005))
Recruiting
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
- Oral repotrectinib (TPX-0005)
-
Yuma, Arizona
- +175 more
Jan 25, 2023